GlobeNewswire·Nov 6, 2026, 9:00 AM ET

BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026

BriaCell Therapeutics and BriaPro presented four preclinical posters at the SITC 41st Annual Meeting in Phoenix, AZ, from November 4-8, 2026.
Bria-OTS+ demonstrated broad innate & adaptive immune activation, potent cancer-cell killing across multiple tumor lines, & sustained cytotoxic activity in repeated challenges.
BP-80, a soluble CD80 dimer, showed CD28 co-stimulatory activity & counteracted CTLA-4 inhibition in cell assays.
A four-week GLP nonhuman primate study confirmed BP-80 tolerability with no treatment-related pathology & a No Observed Effect Level of 50 mg/kg/dose.
TILsRx-001, a B7-H3-targeting construct, antagonized PD-L1 inhibition & exhibited 49-fold higher binding affinity for PD-L1 due to engineered CD80 mutations.
Structure-guided engineering created a CD80 variant with >130-fold stronger PD-L1 binding than wild-type CD80 while maintaining minimal effect on CD28 affinity.
CEO William V. Williams stated these findings support continued development of the immunotherapy pipeline for breast & prostate cancer indications.